HRP20180330T1 - Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om - Google Patents
Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om Download PDFInfo
- Publication number
- HRP20180330T1 HRP20180330T1 HRP20180330TT HRP20180330T HRP20180330T1 HR P20180330 T1 HRP20180330 T1 HR P20180330T1 HR P20180330T T HRP20180330T T HR P20180330TT HR P20180330 T HRP20180330 T HR P20180330T HR P20180330 T1 HRP20180330 T1 HR P20180330T1
- Authority
- HR
- Croatia
- Prior art keywords
- cycloastragenol
- hydroxy
- compositions
- methods
- xylopyranoside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 108010017842 Telomerase Proteins 0.000 title 1
- WENNXORDXYGDTP-UOUCMYEWSA-N cycloastragenol Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O WENNXORDXYGDTP-UOUCMYEWSA-N 0.000 claims 5
- WENNXORDXYGDTP-UHFFFAOYSA-N cyclosiversigenin Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(O)C4(C)C)C4C(O)CC3C2(C)CC1O WENNXORDXYGDTP-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- KNESISUQBYQIIU-UHFFFAOYSA-N 6-Angeloyl-1,6-Dihydroxyfuranoeremophilan-9-one Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CC=C3C4(C)CCC(O)C(C)(C)C4C(O)CC3C2(C)CC1O KNESISUQBYQIIU-UHFFFAOYSA-N 0.000 claims 1
- KZGXEJKMJNLRSF-UHFFFAOYSA-N Astragenol Natural products CC(C)(O)C1CCC(C)(O1)C2C(O)CC3(C)C4CC(O)C5(C)C(C)(C)C(O)CCC5(C)C4=CCC23C KZGXEJKMJNLRSF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 150000008505 β-D-glucopyranosides Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Claims (5)
1. Izdvojeni spoj formule I:
[image]
,
gdje:
X1 je hidroksi ili β-d-ksilopiranozid, X2 je hidroksi ili β-d-glukopiranozid, i
X3 je hidroksi;
OR1 je hidroksi;
i
R2 tvori, zajedmo s ugljikom 9, kondenzirani ciklopropilni prsten, a ---- predstavlja jednostruku vezu između ugljika 9 i 11,
naznačen time što je u količini djelotvornoj za upotrebu u liječenju infekcije HIV-om.
2. Astragalozid IV 16-on, naznačen time što je u količini djelotvornoj za upotrebu u liječenju infekcije HIV-om.
3. Farmaceutski pripravak, naznačen time što sadrži, u farmaceutski prihvatljivom vehikulumu, spoj koji se bira između astragalozid IV 16-ona, cikloastragenol 6-β-d-glukopiranozida i cikloastragenol 3-β-d-ksilopiranozida.
4. Farmaceutski pripravak, naznačen time što sadrži topikalnu formulaciju izdvojenog spoja koji se bira između cikloastragenola, astragenola, astragalozid IV 16-ona, cikloastragenol 6-β-d-glukopiranozida i cikloastragenol 3-β-d-ksilopiranozida.
5. Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni spoj prisutan u navedenoj formulaciji u koncentraciji od najmanje 0,1% (tež./vol.).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48098803P | 2003-06-23 | 2003-06-23 | |
| PCT/US2004/020277 WO2005000245A2 (en) | 2003-06-23 | 2004-06-23 | Compositions and methods for increasing telomerase activity |
| EP04777032.6A EP1644009B1 (en) | 2003-06-23 | 2004-06-23 | Compositions for increasing telomerase activity and treating hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180330T1 true HRP20180330T1 (hr) | 2018-04-20 |
Family
ID=33551962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180330TT HRP20180330T1 (hr) | 2003-06-23 | 2018-02-23 | Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om |
| HRP20190322TT HRP20190322T1 (hr) | 2003-06-23 | 2019-02-18 | Pripravci namijenjeni povećavanju aktivnosti telomeraze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190322TT HRP20190322T1 (hr) | 2003-06-23 | 2019-02-18 | Pripravci namijenjeni povećavanju aktivnosti telomeraze |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7846904B2 (hr) |
| EP (2) | EP1644009B1 (hr) |
| JP (4) | JP5583882B2 (hr) |
| KR (3) | KR101312389B1 (hr) |
| CN (1) | CN1809364B (hr) |
| AP (1) | AP2280A (hr) |
| AU (2) | AU2004251753C1 (hr) |
| BR (1) | BRPI0411856A (hr) |
| CA (1) | CA2528483C (hr) |
| CY (2) | CY1119951T1 (hr) |
| DK (2) | DK2548880T3 (hr) |
| EA (1) | EA009442B1 (hr) |
| ES (2) | ES2666864T3 (hr) |
| HR (2) | HRP20180330T1 (hr) |
| HU (2) | HUE036559T2 (hr) |
| LT (2) | LT2548880T (hr) |
| MX (1) | MXPA05013844A (hr) |
| NZ (1) | NZ544191A (hr) |
| PL (2) | PL2548880T3 (hr) |
| PT (2) | PT1644009T (hr) |
| SI (2) | SI1644009T1 (hr) |
| TR (2) | TR201802543T4 (hr) |
| WO (1) | WO2005000245A2 (hr) |
| ZA (1) | ZA200509846B (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| KR101312389B1 (ko) * | 2003-06-23 | 2013-09-27 | 제론 코포레이션 | 텔로머라제 활성을 증가시키기 위한 조성물 및 방법 |
| US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
| WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| US8197860B2 (en) * | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
| CN100333731C (zh) * | 2005-09-08 | 2007-08-29 | 南京医科大学 | 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用 |
| CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
| US7992749B2 (en) | 2006-03-30 | 2011-08-09 | Nike, Inc. | Support element for a carry strap |
| PL2898887T3 (pl) | 2006-10-30 | 2019-05-31 | Geron Corp | Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu |
| US8604245B2 (en) * | 2007-06-04 | 2013-12-10 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
| CN101225424B (zh) * | 2007-09-13 | 2013-05-29 | 天津药物研究院 | 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用 |
| US8168596B2 (en) * | 2008-10-17 | 2012-05-01 | Nuliv Holding Inc. | Use of cycloartane compounds for treating arthritis |
| US8481721B2 (en) | 2009-05-18 | 2013-07-09 | Telomerase Activation Sciences, Inc. | Compositions and methods for increasing telomerase activity |
| US20160081912A1 (en) * | 2013-05-15 | 2016-03-24 | Fybrands Corp. | Compositions for improving the hair, skin, and nails |
| JP6657101B2 (ja) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | 糖尿病及びそれから生じる疾患合併症の治療のための化合物 |
| CN104435371A (zh) * | 2014-12-06 | 2015-03-25 | 郭亮 | 一种用于治疗关节炎的药酒 |
| CN104491185A (zh) * | 2014-12-06 | 2015-04-08 | 郭亮 | 一种祛风湿药酒及其制备方法 |
| CN104435370A (zh) * | 2014-12-06 | 2015-03-25 | 王香平 | 风湿保健酒 |
| KR20160069857A (ko) | 2014-12-09 | 2016-06-17 | (주)스피어테크 | 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법 |
| CN104817610A (zh) * | 2015-03-15 | 2015-08-05 | 北京化工大学 | 利用硫酸水解制备环黄芪醇的方法 |
| US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| JP6964068B2 (ja) | 2015-04-03 | 2021-11-10 | プロパジェニクス インコーポレイテッド | 上皮細胞のエキソビボ増殖 |
| CN106474094A (zh) * | 2015-08-31 | 2017-03-08 | 南京理工大学 | 一种环黄芪醇电纺纤维膜及其制备方法 |
| JP6869231B2 (ja) | 2015-09-11 | 2021-05-12 | プロパジェニクス インコーポレイテッド | ｅｘ ｖｉｖｏでの上皮細胞の増殖 |
| CN106307522A (zh) * | 2016-11-06 | 2017-01-11 | 谭淞文 | 一种抗衰老保健品及其制备方法和食用方法 |
| CN106831927B (zh) * | 2017-02-07 | 2018-02-09 | 江西师范大学 | 一种黄芪甲苷的合成方法 |
| CN108498521B (zh) * | 2017-02-24 | 2020-05-05 | 北京大学 | 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用 |
| US10098922B1 (en) | 2017-11-30 | 2018-10-16 | Optigenex, Inc. | Increasing telomere length in a cell |
| CA3145888A1 (en) * | 2018-07-31 | 2020-02-06 | Isilay KAVADARLI | Ophthalmic formulations and uses thereof |
| KR102655940B1 (ko) | 2018-08-13 | 2024-04-11 | (주)아모레퍼시픽 | 신규 진세노사이드, 및 이를 포함하는 항염 조성물 |
| CN111053782B (zh) | 2018-10-17 | 2024-07-05 | 株式会社爱茉莉太平洋 | 包含人参皂苷的组合物 |
| KR102635196B1 (ko) | 2018-10-17 | 2024-02-13 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 미백 조성물 |
| US11000538B2 (en) | 2018-10-31 | 2021-05-11 | Amorepacific Corporation | Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside |
| WO2020131058A1 (en) * | 2018-12-20 | 2020-06-25 | Muhammed Majeed | Telomerase enhancement potential of ecdysterone |
| CN109942663B (zh) * | 2019-04-22 | 2021-10-26 | 中国人民解放军联勤保障部队第九八九医院 | 利用双相酸水解制备环黄芪醇的方法 |
| MX2019006749A (es) | 2019-06-10 | 2022-11-28 | Univ Mexico Nac Autonoma | Compuestos activadores de senescencia celular. |
| KR20210037256A (ko) | 2019-09-27 | 2021-04-06 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물 |
| KR20210037257A (ko) | 2019-09-27 | 2021-04-06 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물 |
| CN111419854B (zh) * | 2020-05-18 | 2021-03-30 | 南通大学 | 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用 |
| CN113480628B (zh) * | 2021-08-17 | 2022-06-21 | 贵州师范大学 | 一种贵州疣螈多肽tk-cath及其编码基因和应用 |
| CN113968894B (zh) * | 2021-11-05 | 2024-05-28 | 山西大学 | 一种用黄芪甲苷降解制备环黄芪醇的方法 |
| KR102666469B1 (ko) * | 2023-05-04 | 2024-05-17 | 주식회사 아리바이오 | 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6212791A (ja) | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン、その単離法およびその用途 |
| JPS6212792A (ja) * | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン類の単離法 |
| IT1259645B (it) | 1992-04-10 | 1996-03-25 | Solis Srl | Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione |
| US6007989A (en) | 1992-05-13 | 1999-12-28 | Board Of Regents, The University Of Texas System | Methods of screening for compounds that derepress or increase telomerase activity |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| FR2695561B1 (fr) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| JPH07238026A (ja) * | 1994-02-25 | 1995-09-12 | Pola Chem Ind Inc | 動脈硬化抑制剤及びこれを含む食品又は医薬 |
| AT402890B (de) | 1994-03-16 | 1997-09-25 | Berbi Gmbh | Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| ES2251720T3 (es) * | 1994-07-07 | 2006-05-01 | Geron Corporation | Telomerasa de mamifero. |
| US6162459A (en) | 1995-02-24 | 2000-12-19 | National Science Council | Acyclovir transdermal delivery system |
| AUPN411195A0 (en) | 1995-07-10 | 1995-08-03 | Cathay Herbal Laboratories Pty Ltd | Medicinal composition |
| CN1079265C (zh) | 1995-08-01 | 2002-02-20 | 裴国增 | 灵芝口服液及其配制方法 |
| US5785977A (en) | 1996-02-07 | 1998-07-28 | Breithbarth; Richard | Non-metallic microparticle carrier materials |
| US5916565A (en) | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| TW452494B (en) | 1996-03-12 | 2001-09-01 | Jang De Shan | Herbal composition for stimulating blood circulation |
| US5900226A (en) | 1997-04-09 | 1999-05-04 | Uop Llc | Drying agents for non-foamed polyurethanes |
| JPH1036388A (ja) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | ジンセノサイド類含有ｈｓｐ４７合成抑制剤 |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| WO1998014592A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
| DK0988044T3 (da) | 1997-01-28 | 2008-05-13 | Amelio Frank D | Vand/ethanol-planteekstrakt af Centipeda cunninghamii |
| US5786343A (en) | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| AU748441B2 (en) | 1997-09-05 | 2002-06-06 | Procter & Gamble Company, The | Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients |
| JP2001516712A (ja) | 1997-09-12 | 2001-10-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚又は毛髪用クレンジング及びコンディショニング製品 |
| AU759437B2 (en) | 1998-01-12 | 2003-04-17 | Cold Spring Harbor Laboratory | Extension of cellular lifespan, methods and reagents |
| GB9815177D0 (en) | 1998-07-13 | 1998-09-09 | King S College London | Treatment of skin disorders |
| AU5338199A (en) | 1998-08-09 | 2000-02-28 | Geron Corporation | Methods and compositions for inhibiting or stimulating telomerase assembly |
| CA2352486A1 (en) | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| JP2000204091A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Suisan Kaisha Ltd | 新規ベンゾジオキソ―ル誘導体 |
| JP2000229827A (ja) * | 1999-02-05 | 2000-08-22 | Kose Corp | 皮膚外用剤 |
| JP2000229834A (ja) * | 1999-02-10 | 2000-08-22 | Kanebo Ltd | 化粧料 |
| AUPQ127399A0 (en) | 1999-06-29 | 1999-07-22 | Guangzhou University Of Traditional Chinese Medicine | Compositions and methods for treating or preventing osteoporosis |
| EP1992634A1 (en) | 1999-09-10 | 2008-11-19 | Geron Corporation | Oligonucleotide n3'- p5' thiophosphoramidates: their synthesis and use |
| JP2001258505A (ja) * | 2000-03-24 | 2001-09-25 | Fancl Corp | 食品組成物 |
| CA2307393A1 (en) * | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US6277396B1 (en) | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
| WO2001092289A1 (fr) | 2000-05-31 | 2001-12-06 | Japan Science And Technology Corporation | Promoteurs de regeneration de tissu cutane contenant le ginsenoside rb1 |
| CN1172677C (zh) | 2000-07-14 | 2004-10-27 | 复旦大学附属中山医院 | 黄芪甲苷在制备药物组合物中的应用 |
| WO2002007732A2 (en) * | 2000-07-26 | 2002-01-31 | Cambridge University Technical Services Limited | Use of panaxatriol for stimulation angiogenesis |
| GB0105613D0 (en) | 2001-03-07 | 2001-04-25 | Univ Cambridge Tech | Pharmaceutically effective compounds and their use |
| US6696094B2 (en) | 2000-10-18 | 2004-02-24 | Tzu-Sheng Wu | Herbal pharmaceutical composition for treatment of HIV/AIDS patients |
| CN1242807C (zh) * | 2000-11-08 | 2006-02-22 | 天津市延龄营养保健品有限公司 | 一种抗皮肤过敏的药物组合物及其制法和用途 |
| CN1369276A (zh) * | 2001-02-12 | 2002-09-18 | 徐秀荣 | 有效减轻体重的组合物和方法 |
| JP2002275086A (ja) * | 2001-03-15 | 2002-09-25 | Fancl Corp | 虚弱体質改善用組成物 |
| US7262174B2 (en) | 2001-05-09 | 2007-08-28 | Geron Corporation | Treatment for wounds |
| US20020182272A1 (en) | 2001-05-30 | 2002-12-05 | Bruce Halstead | Methods of treatment of HIV-associated conditions |
| JP2003089687A (ja) * | 2001-07-03 | 2003-03-28 | Tanabe Seiyaku Co Ltd | 新規ブタジエン誘導体、その製法およびその合成中間体 |
| CN1522248A (zh) | 2001-07-03 | 2004-08-18 | 田边制药株式会社 | 新型丁二烯衍生物,制备它的方法及合成它的中间体 |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US20030108629A1 (en) | 2001-07-17 | 2003-06-12 | Chou Wen Hsien | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| CN1164608C (zh) * | 2001-08-31 | 2004-09-01 | 上海中医药大学 | 具有抗心肌纤维化作用的黄芪皂甙甲 |
| CN1406585A (zh) | 2001-09-07 | 2003-04-02 | 中国科学院上海药物研究所 | 一种治疗病毒性心肌炎的药物组合物 |
| JP2003160497A (ja) * | 2001-11-22 | 2003-06-03 | Toshin Kagaku Kk | 皮膚外用剤 |
| US20070042962A1 (en) | 2002-02-04 | 2007-02-22 | Adams David S | Peptide dependent upregulation of telomerase expression |
| CN1236803C (zh) | 2002-03-20 | 2006-01-18 | 郑国芃 | 一种治疗风湿症的中药 |
| CN1189176C (zh) * | 2002-07-22 | 2005-02-16 | 江苏正大天晴药业股份有限公司 | 黄芪甲甙组合物及其制备方法 |
| WO2004096251A1 (en) * | 2003-03-26 | 2004-11-11 | Westlake Partners | Herbal compositions and methods for effecting weight loss in humans |
| CA2529852A1 (en) * | 2003-06-20 | 2004-12-29 | Viral Genomix, Inc. | Compositions for and methods for treating hiv |
| KR101312389B1 (ko) | 2003-06-23 | 2013-09-27 | 제론 코포레이션 | 텔로머라제 활성을 증가시키기 위한 조성물 및 방법 |
| US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
| US20070122501A1 (en) | 2003-06-27 | 2007-05-31 | Hong Kong University Of Science And Technology | Formulations containing astragalus extracts and uses thereof |
-
2004
- 2004-06-23 KR KR1020057024720A patent/KR101312389B1/ko active IP Right Grant
- 2004-06-23 BR BRPI0411856-1A patent/BRPI0411856A/pt not_active Application Discontinuation
- 2004-06-23 ZA ZA200509846A patent/ZA200509846B/en unknown
- 2004-06-23 MX MXPA05013844A patent/MXPA05013844A/es active IP Right Grant
- 2004-06-23 HU HUE04777032A patent/HUE036559T2/hu unknown
- 2004-06-23 CA CA2528483A patent/CA2528483C/en not_active Expired - Lifetime
- 2004-06-23 NZ NZ544191A patent/NZ544191A/en not_active IP Right Cessation
- 2004-06-23 CN CN2004800172464A patent/CN1809364B/zh not_active Expired - Lifetime
- 2004-06-23 LT LTEP12180710.1T patent/LT2548880T/lt unknown
- 2004-06-23 JP JP2006517617A patent/JP5583882B2/ja not_active Expired - Lifetime
- 2004-06-23 KR KR1020137031630A patent/KR101465515B1/ko not_active Expired - Lifetime
- 2004-06-23 TR TR2018/02543T patent/TR201802543T4/tr unknown
- 2004-06-23 EP EP04777032.6A patent/EP1644009B1/en not_active Expired - Lifetime
- 2004-06-23 DK DK12180710.1T patent/DK2548880T3/en active
- 2004-06-23 DK DK04777032.6T patent/DK1644009T3/en active
- 2004-06-23 TR TR2019/03587T patent/TR201903587T4/tr unknown
- 2004-06-23 SI SI200432425T patent/SI1644009T1/en unknown
- 2004-06-23 AP AP2005003474A patent/AP2280A/xx active
- 2004-06-23 EA EA200600076A patent/EA009442B1/ru unknown
- 2004-06-23 LT LTEP04777032.6T patent/LT1644009T/lt unknown
- 2004-06-23 WO PCT/US2004/020277 patent/WO2005000245A2/en active Application Filing
- 2004-06-23 ES ES04777032.6T patent/ES2666864T3/es not_active Expired - Lifetime
- 2004-06-23 HU HUE12180710A patent/HUE043168T2/hu unknown
- 2004-06-23 PL PL12180710T patent/PL2548880T3/pl unknown
- 2004-06-23 EP EP12180710.1A patent/EP2548880B1/en not_active Expired - Lifetime
- 2004-06-23 SI SI200432463T patent/SI2548880T1/sl unknown
- 2004-06-23 AU AU2004251753A patent/AU2004251753C1/en not_active Ceased
- 2004-06-23 ES ES12180710T patent/ES2716528T3/es not_active Expired - Lifetime
- 2004-06-23 PT PT47770326T patent/PT1644009T/pt unknown
- 2004-06-23 PT PT12180710T patent/PT2548880T/pt unknown
- 2004-06-23 PL PL04777032T patent/PL1644009T3/pl unknown
- 2004-06-23 US US10/562,374 patent/US7846904B2/en active Active
- 2004-06-23 KR KR1020117017367A patent/KR20110089887A/ko active Application Filing
-
2008
- 2008-11-25 AU AU2008249200A patent/AU2008249200A1/en not_active Abandoned
-
2010
- 2010-03-05 US US12/718,812 patent/US8759304B2/en not_active Expired - Lifetime
-
2011
- 2011-02-21 JP JP2011035191A patent/JP5841337B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-23 JP JP2013219989A patent/JP5913253B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-24 US US14/313,698 patent/US20150093455A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000130A patent/JP2016041770A/ja not_active Withdrawn
-
2018
- 2018-02-23 HR HRP20180330TT patent/HRP20180330T1/hr unknown
- 2018-02-26 CY CY20181100225T patent/CY1119951T1/el unknown
-
2019
- 2019-02-18 HR HRP20190322TT patent/HRP20190322T1/hr unknown
- 2019-03-22 CY CY20191100342T patent/CY1121447T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180330T1 (hr) | Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om | |
| CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| CA2464250A1 (en) | Kit for the preparation of a pharmaceutical composition | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| AU2337197A (en) | Cinnamic acid derivatives and their use as integrin antagonists | |
| BG103969A (en) | C-4"-substituted macrolide derivatives | |
| TR200901979T2 (tr) | Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri. | |
| EP1283054A4 (en) | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF | |
| YU72602A (sh) | Hidrofilni molekularni disperzioni rastvori karvedilola | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| MXPA04003192A (es) | Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas. | |
| JP2007510712A (ja) | 殺菌組成物ならびにその作製方法および使用方法 | |
| CA2450359A1 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| CA2271162A1 (en) | Stearidonic acid compositions and uses thereof | |
| WO2004087141B1 (en) | Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases | |
| JP2003514025A5 (hr) | ||
| ATE437636T1 (de) | Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| DE60005517D1 (de) | Kaliumkanal-blockierende mittel | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
| CA2348693A1 (en) | Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid | |
| CA2423288A1 (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
| ATE259778T1 (de) | Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten | |
| CA1207238A (en) | Use of haloprogin in the treatment of herpes labialis |